NCT02071368View on ClinicalTrials.gov

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Healthy
Interventions
DRUG

Canagliflozin, 300 mg

Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).

DRUG

Metformin XR, 500 mg

Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).

DRUG

CANA/MET XR FDC, Formulation 1, 150 mg/500

Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.

DRUG

CANA/MET XR FDC, Formulation 2, 150 mg/500 mg

Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02071368 - A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants | Biotech Hunter | Biotech Hunter